In 2013, Arna defended her thesis on benefit-risk assessment of pharmaceuticals, including post marketing safety and different views of stakeholders regarding acceptance of new drugs to the market. Before she started her PhD, she had been working in the RA department of an Icelandic pharma company. Arna has experience with the overall European CTD dossier, having written and maintained sections from Modules 1 through 5, building on her knowledge in CMC, RA and clinical requirements. Arna has developed an expertise in Good Clinical Practice and is qualified to perform GCP audits. Arna also is responsible for developing DADA’s Pharmaceutical Safety and Efficacy services.